Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Protein-polysaccharide conjugate vaccines that protect against Haemophilus influenzae type b (Hib), serogroup C Neisseria meningitidis, and multiple capsular serotypes of Streptococcus pneumoniae have had a major impact on invasive bacterial disease in childhood when incorporated into routine infant immunization schedules. However, effectiveness data from the United Kingdom suggest that primary infant immunization alone may not be associated with long-term protection. Both immunological priming and antibody persistence are important aspects of long-term protection induced by these vaccines. An improved understanding of the immunobiology of the B-cell response to these vaccines may direct development of immunization strategies that provide sustained protection.

Original publication

DOI

10.1001/jama.294.23.3019

Type

Journal article

Journal

JAMA

Publication Date

21/12/2005

Volume

294

Pages

3019 - 3023

Keywords

Antibodies, Bacterial, Antibody Affinity, B-Lymphocyte Subsets, B-Lymphocytes, Bacterial Capsules, Bacterial Vaccines, Child, Haemophilus Vaccines, Humans, Immunization, Secondary, Immunologic Memory, Infant, Meningococcal Vaccines, Plasma Cells, Polysaccharides, Bacterial, Vaccination, Vaccines, Conjugate